BRB 002
Alternative Names: BRB-002Latest Information Update: 13 Jan 2025
Price :
$50 *
At a glance
- Originator Bitterroot Bio
- Class Anti-inflammatories; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atherosclerosis
- Preclinical Vasculitis
Most Recent Events
- 08 Jan 2025 Pharmacodynamics and adverse events data from a phase I trial in Atherosclerosis released by Bitterroot Bio
- 08 Jan 2025 Bitterroot Bio completes a phase I trial for Atherosclerosis in an unknown location
- 30 Oct 2024 Bitterroot Bio completes enrolment in a phase I trial for Atherosclerosis in an unknown location